Adimmune yesterday said that the Indonesian trials would determine the optimal dosage for its vaccine to generate adequate protection against COVID-19 variants and prove its efficacy. The name of Adimmune Corp is pictured at the company’s headquarters in Taichung in an undated photograph. Despite encountering a setback in Taiwan, Adimmune did not modify the formula of its COVID-19 vaccine, dubbed AdimrSC-2f, nor its recombinant protein manufacturing technology, Pan said. Instead, the company plans to apply to the Indonesian regulator to conduct a phase 3 trial there, he said. As with Moderna Inc, Adimmune would consider combining its flu vaccine into COVID-19 vaccine if its candidate is approved, although that mixture would not be a focus for research and development at this time, Pan said.

Source: Taipei Times September 13, 2021 15:56 UTC